TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00200161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
Study: NCT01502007

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerometer feedback and lifestyle counseling
Description: Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerometer without Feedback
Description: The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
Study: NCT06229639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passy Muir Valve
Study: NCT03431337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg
Description: Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (lactase)
Description: Placebo (in place of additional amoxicillin in experimental arm)
Study: NCT04592419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study: NCT01762228

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical stimulation
Description: Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRPV1 agonist
Description: Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
Study: NCT03110380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg FDC tablet(s) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F/TAF
Description: 200/25 mg FDC tablet(s) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DTG
Description: 50 mg tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG Placebo
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F/TAF Placebo
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablet(s) administered orally once daily
Study: NCT02461238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vouchers
Description: The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
Study: NCT02700971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Microscope Diagnostic system
Description: Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
Study: NCT02301533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shikamana Intervention
Description: See arm description

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Care
Description: See arm description
Study: NCT03848858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR plus TAU
Description: The standard EMDR protocol will first be applied, consisting of 8 phases: 1) Patient history; 2) Patient preparation; 3) Evaluation of the main aspects of the traumatic memory; 4) Desensitization of the memory; 5) Installation of the positive cognition; 6) Body scan; 7) Close and 8) Reevaluation. The specific protocol for the sequelae of somatic illness and medical trauma is next applied. It first focuses on processing past memories related to diagnosis, symptom development, medical procedures and unjust or stressful behaviour with the medical system. Once these are processed, the intervention addresses current symptoms, impairments and triggers. Finally, the patient is helped to face the future and reduce avoidance of medical procedures, avoidance of social life and fear of dying.
Study: NCT02577133

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consisted of an identical bottle with distilled water
Study: NCT04073134

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Study: NCT00630903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUVA (8MOP + UVA) + IFN
Description: Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUVA (8-MOP + UVA)
Description: Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
Study: NCT00636324

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal CPAP, level 7 to 9 cmH2O
Description: Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP, level 4 to 6 cmH2O
Description: Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
Study: NCT01165476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treprostinil diethanolamine
Description: sustained release tablets. One 1mg tablet per period. Two total doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil diethanolamine
Description: sustained release tablets. One 1mg tablet per period. Two total doses.
Study: NCT02767947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1%
Description: Luliconazole cream will be applied per schedule specified in the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle cream will be applied per schedule specified in the arm.
Study: NCT02805413

Intervention type: OTHER
Group type: OTHER
Intervention: Détermination and comparison of blood pressure
Description: Rebreathings will be performed every parabola (2, 4, 6, 8, 10...). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9...). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
Study: NCT03039036

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: Artificially rupturing membranes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotomy
Description: Artificially rupturing membranes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley Catheter
Description: Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
Study: NCT04000191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAC
Description: Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAC
Description: Monitored anesthesia care (MAC) administered by anesthesiology and Injection of local anesthesia mixture of 1% lidocaine with epinephrine and 0.25% Marcaine by the operating surgeon.
Study: NCT06229639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheostomy Plug
Study: NCT00199485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angelica Sinensis
Description: Angelica Sinensis / placebo
Study: NCT04000191

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perianal ice application
Description: Application of ice to the perianal area after the area is prepared with betadine, prior to injection of local anesthesia by the surgeon.
Study: NCT02476305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryoprobes
Description: Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
Study: NCT05072821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A Injection [Botox]
Description: After the whole surgical procedures of keloid revision are done, the participants will receive Botulinum Toxin type A (BTA) injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Vials containing 100 units of BTA (BotoxⓇ, Allergan) are mixed with 2mL 0.9% injectable saline. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was treated, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 8 units / cm based on aforementioned studies. The maximal dose won't exceed 100 units.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: After the whole surgical procedures of keloid revision are done, the participants will receive 0.9% saline injection. The investigators split the scar into the right side and the left side. BTA and 0.9% saline, respectively, are used for the two arms of the study. Only 0.9% saline is injected on the control side. The injection depth will be the intradermal layer. Injections will be performed with a 30-gauge needle and 1 mL syringe. Just before skin closure, the entire scar was injected, with sides randomized to receive treatment with either BTA or 0.9% normal saline. The dosage is 0.16 mL / cm.
Study: NCT02910687

Intervention type: OTHER
Intervention: This is an observational study
Study: NCT03114358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Carbapenem de-escalation
Description: The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
Study: NCT04423445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture combined with acupressure
Description: Participants received laser acupuncture on the six selected acupuncture points bilaterally twice a week for 4 weeks. A seed was taped onto each of the three points of the unilateral ear (initially, the left ear), where it remained for five days. Pressing on each of the seeds for one minute three times a day was required, but the stimulation intensity was adjusted depending on the participant's individual tolerance. The de qi sensation appears to be an established intervention efficacy indicator during auricular acupressure. After five days, the seed was removed, and a new seed was taped on the other ear.
Study: NCT04601493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture Nudge
Description: During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture Nudge
Description: During the choice architecture nudge intervention, Primary Care Providers (PCPs) will be sent alerts in the Electronic Health Record (EHR) system when they initiate an opioid order for a patient who has not had an opioid prescription within the past six months. The alert provides guidance language about opioid prescribing and prompts the PCP to open the SmartSet to order non-opioid treatment alternatives. PCPs can choose to ignore this, but opening the SmartSet is the default option. When the SmartSet is opened, PCPs can choose to click on a variety of treatment order options, including both non-opioid pharmacological options and non-pharmacological options (e.g., referral to physical therapy or pain clinic).
Study: NCT01616199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.~Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.~Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: vemurafenib is a B-Raf enzyme inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: vemurafenib is a B-Raf enzyme inhibitor
Study: NCT04601493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMP Integration & Nudge
Description: During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMP Integration & Nudge
Description: During the Prescription Drug Monitoring Program (PMP) integration \& nudge intervention, Primary Care Providers (PCPs) will have integrated access to the PMP embedded within the EHR. All clinicians can already access the PMP to look up a patient's prior opioid prescriptions and prescription fills. However, this process involves signing in to the separate PMP website and can be complicated and time-consuming within typical clinical workflow. The integrated PMP tool makes it much easier and faster for a PCP to access the PMP information for a given patient.
Study: NCT01616199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vemurafenib
Description: vemurafenib is a B-Raf enzyme inhibitor
Study: NCT02461238

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition education
Description: Nutrition education workshops taught by a dietician

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: Nutrition education workshops taught by a dietician
Study: NCT04689698

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thomayer test
Description: Testing of the ankle in sagittal line and Thomayer test before and after flossing of sole.
Study: NCT06048887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN04894 Oral Solution
Description: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRN04894 Oral Solution
Description: CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Solution
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Solution
Description: Placebo
Study: NCT02342938

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MEG or fMRI And INtracranial EEG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI